Table 1 Effects of Liraglutide on hepatic and systemic hemodynamics, and biochemical parameters in rats with chronic liver disease due to chronic TAA administration, represented as mean ± s.e.m.

From: Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies

  Vehicle n = 11 Liraglutide n = 11 p value
PP (mmHg) 11.6 ± 0.8 9.3 ± 1.0 0.03
MAP (mmHg) 99.5 ± 7.2 89.9 ± 7.1 0.4
PBF (mL/min) 11.9 ± 1.0 11.5 ± 2.3 0.5
HVR (mmHg·min·mL−1·g−1) 9.5 ± 1.8 5.7 ± 1.3 0.1
ex vivo HVR (mmHg·min·mL−1·g−1) 1.6 ± 0.3 0.9 ± 0.04 0.07
Body weight pre-treatment (g) 289 ± 12 288 ± 7 0.5
Body weight post-treatment (g) 310 ± 9 274 ± 9 0.03
Liver weight (g) 8.4 ± 0.7 6.7 ± 0.4 0.1
AST (U/L) 105 ± 14 126 ± 14 0.3
ALT (U/L) 61 ± 10 67 ± 4 0.5
Albumin (g/L) 15.3 ± 1.3 16.3 ± 0.5 0.5
Cholesterol (mg/dL) 54.0 ± 8.3 44.6 ± 5.8 0.4
TG (mg/dL) 31.2 ± 5.6 26.8 ± 3.4 0.5
FFA (µmol/L) 506 ± 66 477 ± 55 0.7
PP, portal pressure; MAP, mean arterial pressure; PBF, portal blood flow; HVR, hepatic vascular resistance; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TG, triglycerides; FFA, free fatty acids.